Filing Details

Accession Number:
0000914190-20-000195
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-01 17:58:18
Reporting Period:
2020-05-28
Accepted Time:
2020-06-01 17:58:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
842023 Bio-Techne Corp TECH Biological Products, (No Disgnostic Substances) (2836) 411427402
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1270905 David Norman Eansor 8100 Southpark Way, A-8
Littleton CO 80120
President-Protein Sciences No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-05-28 3,448 $108.49 3,448 No 4 M Direct
Common Stock Disposition 2020-05-28 3,448 $260.19 0 No 4 S Direct
Common Stock Acquisiton 2020-05-29 7,909 $108.49 7,909 No 4 M Direct
Common Stock Disposition 2020-05-29 1,700 $260.83 6,209 No 4 S Direct
Common Stock Disposition 2020-05-29 3,400 $261.74 2,809 No 4 S Direct
Common Stock Disposition 2020-05-29 2,100 $262.68 709 No 4 S Direct
Common Stock Disposition 2020-05-29 709 $264.01 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options (Right to Buy) Disposition 2020-05-28 3,448 $0.00 3,448 $108.49
Common Stock Stock Options (Right to Buy) Disposition 2020-05-29 7,909 $0.00 7,909 $108.49
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,909 2022-08-07 No 4 M Direct
0 2022-08-07 No 4 M Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock Stock Options (Right to Buy) $106.59 2023-08-18 14,114 14,114 Direct
Common Stock Stock Options (Right to Buy) $106.59 2023-08-18 18,819 18,819 Direct
Common Stock Restricted Stock Units $0.00 2,174 2,174 Direct
Common Stock Stock Options (Right to Buy) $125.05 2024-08-09 11,982 11,982 Direct
Common Stock Stock Options (Right to Buy) $125.05 2024-08-09 15,976 15,976 Direct
Common Stock Restricted Stock Units $0.00 2,537 2,537 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 13,550 13,550 Direct
Common Stock Stock Options (Right to Buy) $177.32 2025-08-08 18,066 18,066 Direct
Common Stock Restricted Stock Units $0.00 3,151 3,151 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 15,948 15,948 Direct
Common Stock Stock Options (Right to Buy) $190.41 2026-08-07 21,265 21,265 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2023-08-18 14,114 14,114 Direct
2023-08-18 18,819 18,819 Direct
2,174 2,174 Direct
2024-08-09 11,982 11,982 Direct
2024-08-09 15,976 15,976 Direct
2,537 2,537 Direct
2025-08-08 13,550 13,550 Direct
2025-08-08 18,066 18,066 Direct
3,151 3,151 Direct
2026-08-07 15,948 15,948 Direct
2026-08-07 21,265 21,265 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.0000 to $260.6600, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $260.2500 to $261.2100, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $261.2500 to $262.2400, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $262.3150 to $263.2300, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $263.6168 to $264.5700, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  6. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
  7. Fully exercisable.
  8. Options to purchase 4,705 shares vest on each of 8/18/2017, 8/18/2018 and 8/18/2019 and options to purchase 4,704 shares vest on 8/18/2020.
  9. Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  10. Options to purchase 3,994 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
  11. Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  12. Options to purchase 4,517 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 4,516 shares vest on each of 8/8/2021 and 8/8/2022.
  13. Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
  14. Options to purchase 5,317 shares vest on 8/7/2020 and options to purchase 5,316 shares vest on each of 8/7/2021, 8/7/2022 and 8/7/2023.